Ecuador earthquake recovery: Sandoz announces financial support and product donation

Holzkirchen, May 23, 2016 – In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.

Hundreds of people lost their lives in the earthquake, which injured thousands more, devastated communities and left approximately 25,000 people living in shelters.

Employees locally have already been actively involved in a variety of relief operations, including preparing emergency kits of food and hygiene items for delivery to the …

/by

Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making

Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.

Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 …

/by

Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making

Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.

Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 …

/by

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by

Novartis publishes updated 2015 segment financials reflecting new division structure

  • Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release

  • No change in audited 2015 Consolidated Financial Statements for the total Group

Basel, March 31, 2016 – Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers …

/by

Novartis publishes updated 2015 segment financials reflecting new division structure

  • Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release

  • No change in audited 2015 Consolidated Financial Statements for the total Group

Basel, March 31, 2016 – Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers …

/by

New research highlights need for a competitive functioning biologics market to achieve full potential of biosimilars for patients, healthcare professionals and payors

New research published today in a report from the IMS Institute for Healthcare Informatics – Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.

The report, funded by Novartis, will …

/by